At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SCNX Scienture Holdings, Inc.
Post-Mkt 05-06 16:59:34 EDT
0.3911
+0.0005
+0.13%
盘后0.4049
+0.0138+3.53%
16:45 EDT
High0.4159Low0.3880Vol511.50K
Open0.4001D1 Closing0.3906Amplitude7.15%
Mkt Cap15.89MTradable Cap13.29MTotal Shares40.63M
T/O207.32KT/O Rate1.50%Tradable Shares33.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Scienture wins third US patent for ARBLI oral suspension, protection through 2041
Reuters  ·  05-06 20:10
Scienture wins third US patent for ARBLI oral suspension, protection through 2041
Scienture Announces Third Patent Grant for Arbli™ (Losartan Potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
THOMSON REUTERS  ·  05-06 20:05
Scienture Announces Third Patent Grant for Arbli™ (Losartan Potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
Scienture Holdings closes USD 11.42 million secured note financing with Streeterville Capital
Reuters  ·  05-02
Scienture Holdings closes USD 11.42 million secured note financing with Streeterville Capital
Scienture granted 180-day extension to meet Nasdaq minimum bid price
TIPRANKS  ·  04-15
Scienture granted 180-day extension to meet Nasdaq minimum bid price
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
GlobeNewswire  ·  04-15
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
GlobeNewswire  ·  04-06
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
BRIEF-Scienture Reports Year End 2025 Financial Results And Provides Business Update
Reuters  ·  03-30
BRIEF-Scienture Reports Year End 2025 Financial Results And Provides Business Update
Scienture FY25 operating loss widens to $42.6 million; gross margin climbs 7,240 bps to 76.8%
Reuters  ·  03-30
Scienture FY25 operating loss widens to $42.6 million; gross margin climbs 7,240 bps to 76.8%
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
GlobeNewswire  ·  03-30
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025
Benzinga  ·  03-30
EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025
Scienture FY25 Revenue $431.6K Vs $136.6K YoY; Net Loss Per Common Share $(2.70) Vs $(5.41) YoY
Benzinga  ·  03-30
Scienture FY25 Revenue $431.6K Vs $136.6K YoY; Net Loss Per Common Share $(2.70) Vs $(5.41) YoY
Scienture Holdings Inc expected to post a loss of 28 cents a share - Earnings Preview
Reuters  ·  03-27
Scienture Holdings Inc expected to post a loss of 28 cents a share - Earnings Preview
Scienture Holdings Inc expected to post a loss of 28 cents a share - Earnings Preview
Reuters  ·  03-20
Scienture Holdings Inc expected to post a loss of 28 cents a share - Earnings Preview
Scienture Shares Surge 48% After Co Signs Deals to Expand Reach of Opioid Overdose Spray
THOMSON REUTERS  ·  03-11
Scienture Shares Surge 48% After Co Signs Deals to Expand Reach of Opioid Overdose Spray
Why Is Scienture Holdings Stock (SCNX) Up Today?
TIPRANKS  ·  03-11
Why Is Scienture Holdings Stock (SCNX) Up Today?
Shares of Scienture up 60.1% Premarket After Co Signs Deals to Expand Reach of Opioid Overdose Spray
THOMSON REUTERS  ·  03-11
Shares of Scienture up 60.1% Premarket After Co Signs Deals to Expand Reach of Opioid Overdose Spray
Scienture signs GPO agreements for REZENOPY reaching over 5,000 U.S. institutions
Reuters  ·  03-11
Scienture signs GPO agreements for REZENOPY reaching over 5,000 U.S. institutions
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
GlobeNewswire  ·  03-11
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
Scienture Holdings Initiated at Buy by Maxim Group
Dow Jones  ·  02-25
Scienture Holdings Initiated at Buy by Maxim Group
Scienture initiated with a Buy at Maxim
TIPRANKS  ·  02-24
Scienture initiated with a Buy at Maxim

Introduction

Company Name.
Scienture Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which offers price transparency, purchasing capabilities, and other value-added services; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Lutz, Florida.
Issue price:
--